SNP
neuroblastoma
pharmacogenetics
survival
toxicity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
26
02
2020
revised:
27
03
2020
accepted:
10
04
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
6
1
2021
Statut:
epublish
Résumé
Single nucleotide polymorphisms (SNPs) in Pharmacogenetics can play an important role in the outcomes of the chemotherapy treatment in Neuroblastoma, helping doctors maximize efficacy and minimize toxicity. Employing AgenaBioscience MassArray, 96 SNPs were genotyped in 95 patients looking for associations of SNP with response to induction therapy (RIT) and grade 3-4 toxicities, in High Risk patients. Associations of SNPs with overall (OS) and event-free (EFS) survival in the whole cohort were also explored. Cox and logistic regression models with Elastic net penalty were employed. Association with grade 3-4 gastrointestinal and infectious toxicities was found for 8 different SNPs. Better RIT was correlated with rs726501 AG, rs3740066 GG, rs2010963 GG and rs1143684 TT (OR = 2.87, 1.79, 1.23, 1.14, respectively). EFS was affected by rs2032582, rs4880, rs3814058, rs45511401, rs1544410 and rs6539870. OS was influenced by rs 1801133, rs7186128 and rs1544410. Remarkably, rs1801133 in
Identifiants
pubmed: 32295184
pii: ijms21082714
doi: 10.3390/ijms21082714
pmc: PMC7215604
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MYCN protein, human
0
N-Myc Proto-Oncogene Protein
0
Receptors, Calcitriol
0
VDR protein, human
0
MTHFR protein, human
EC 1.5.1.20
Methylenetetrahydrofolate Reductase (NADPH2)
EC 1.5.1.20
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI13-00046
Organisme : Fundación Mutua Madrileña
ID : 2016 Ayudas Investigación en Salud
Organisme : Asociación Pablo Ugarte
ID : -
Références
J Clin Oncol. 2017 Aug 1;35(22):2580-2587
pubmed: 28471719
J Clin Oncol. 2009 Jan 10;27(2):298-303
pubmed: 19047290
J Clin Oncol. 2008 Mar 20;26(9):1504-10
pubmed: 18349403
BMC Cancer. 2016 May 27;16:337
pubmed: 27234217
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29286579
Pharmacogenet Genomics. 2008 Jul;18(7):621-31
pubmed: 18551042
J Bone Miner Res. 1999 Feb;14(2):240-7
pubmed: 9933478
Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417
pubmed: 29474005
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63
pubmed: 17537913
Br J Cancer. 2013 Aug 20;109(4):957-64
pubmed: 23860526
Pharmacogenet Genomics. 2012 Feb;22(2):117-33
pubmed: 22143415
Curr Opin Genet Dev. 2017 Feb;42:81-90
pubmed: 28458126
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
PLoS One. 2011;6(10):e26091
pubmed: 22016816
Lancet Oncol. 2018 Dec;19(12):1617-1629
pubmed: 30442501
J Popul Ther Clin Pharmacol. 2011;18:e134-51
pubmed: 21467604
Pharmacogenet Genomics. 2011 Dec;21(12):808-19
pubmed: 21946896
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
J Clin Oncol. 2003 Jun 1;21(11):2077-84
pubmed: 12775732
Klin Padiatr. 2016 Apr;228(3):130-4
pubmed: 27043079
Children (Basel). 2019 Feb 11;6(2):
pubmed: 30754710
J Pediatr. 2009 May;154(5):688-93
pubmed: 19159907
Eur J Cancer. 2019 May;112:66-79
pubmed: 30947024
Cancer Cell. 2012 Mar 20;21(3):362-73
pubmed: 22439933
Cancer Cell. 2017 Oct 9;32(4):427-443.e8
pubmed: 29017055
Int J Mol Sci. 2016 Sep 08;17(9):
pubmed: 27618021
J Biol Chem. 2002 Jul 12;277(28):25125-32
pubmed: 11991950
Heredity (Edinb). 2015 Jan;114(1):107-15
pubmed: 25204301
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Front Pharmacol. 2018 Mar 13;9:158
pubmed: 29593529
Cochrane Database Syst Rev. 2015 May 19;(5):CD010774
pubmed: 25989478
Oncotarget. 2016 Jun 14;7(24):36293-36310
pubmed: 27167114
Am J Hum Genet. 1991 Mar;48(3):536-45
pubmed: 1998339
J Clin Oncol. 2010 Jul 20;28(21):3516-24
pubmed: 20567002
Am J Hematol. 2011 Jan;86(1):98-101
pubmed: 21064136
Clin Cancer Res. 2009 Jun 15;15(12):4165-73
pubmed: 19509150